<DOC>
	<DOC>NCT01681576</DOC>
	<brief_summary>This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.</brief_summary>
	<brief_title>Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Key Written informed consent must be obtained before any study assessment is performed. Males and females of nonchildbearing potential and of legal age (at least 18 years or older as defined by local law). Asian patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy with up to two drugs. Key Women of childbearing potential. History of angioedema, drugrelated or otherwise History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes. Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period. History or evidence of a secondary form of hypertension, Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke. History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening. Current or history of hypertensive retinopathy. Previous or current diagnosis of heart failure (NYHA Class IIIV). Clinically significant valvular heart disease at screening. Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hypertension, salt sensitivity, valsartan, LCZ696</keyword>
</DOC>